title: Tolerability of levetiracetam in elderly patients with CNS disorders.
abstract: The purpose of this analysis was to compare treatment-emergent adverse events (TEAE) related to use of levetiracetam (LEV) reported by young and elderly patients with anxiety and cognitive disorders, and young epilepsy patients. The LEV database includes reports of TEAE from trials of patients with diagnoses of a cognitive disorder (N=719), an anxiety disorder (N=1510), or localization-related epilepsy (N=1023) who participated in clinical trials lasting up to 16 weeks. Patients were grouped as young (<65 years) or elderly (> or = 65 years). The most common TEAE occurring most frequently in the LEV-treated groups were abdominal pain, asthenia, headache, anorexia, weight loss, dizziness, insomnia, somnolence, and tremor. The only significant differences in TEAE were seen between young and elderly groups with anxiety disorders (>3% higher for LEV than for placebo-treated patients) in headache (5.2% elderly, -0.9% young, P=0.041), and tremor (5.2 and -0.5%, respectively, P=0.022) and between young anxiety patients and young epilepsy patients for somnolence (-0.7 and 5.4%, respectively, P=0.036). For the other TEAEs there was no evidence for consistent differences between young and elderly patients and between patients with different CNS disorders. Overall, LEV was well tolerated by all patient groups. The favorable adverse event profile suggests that LEV might be suitable for use by elderly patients.
authors.affiliation: Department of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue (G7E, Room 7-127), West Haven, CT 06516-2770, USA. Joyce.Cramer@Yale.Edu
authors.forename: Joyce A
authors.initials: JA
authors.lastname: Cramer
authors.forename: Ilo E
authors.initials: IE
authors.lastname: Leppik
authors.forename: Katrien De
authors.initials: KD
authors.lastname: Rue
authors.forename: Pascal
authors.initials: P
authors.lastname: Edrich
authors.forename: Günter
authors.initials: G
authors.lastname: Krämer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology; D000927:Anticonvulsants / Q000008:administration & dosage / Q000009:adverse effects*; D001008:Anxiety Disorders / Q000150:complications; D002493:Central Nervous System Diseases / Q000150:complications*; D003072:Cognition Disorders / Q000150:complications; D004827:Epilepsy / Q000150:complications; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D008297:Male; D008875:Middle Aged; D010889:Piracetam / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
chemical_list: D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam